File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study

TitleRamucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study
Authors
Chau, IPeck-Radosavljevic, MBorg, CMalfertheiner, PSeitz, JFPark, JORyoo, BYYen, CJKudo, MPoon, RTPPastorelli, DBlanc, JFChung, HCBaron, ADOkusaka, TBowman, LCui, ZLGirvan, ACAbada, PBYang, LZhu, AX
KeywordsHepatocellular carcinoma
Patient-focused outcomes
Performance status
Quality of life
Ramucirumab
Sorafenib
Issue Date2017
Citation
European Journal of Cancer, 2017, v. 81, p. 17-25 How to Cite?
DOI: http://dx.doi.org/10.1016/j.ejca.2017.05.001
Persistent Identifierhttp://hdl.handle.net/10722/243854
ISI Accession Number ID
WOS:000404894700003

 

DC FieldValueLanguage
dc.contributor.authorChau, I-
dc.contributor.authorPeck-Radosavljevic, M-
dc.contributor.authorBorg, C-
dc.contributor.authorMalfertheiner, P-
dc.contributor.authorSeitz, JF-
dc.contributor.authorPark, JO-
dc.contributor.authorRyoo, BY-
dc.contributor.authorYen, CJ-
dc.contributor.authorKudo, M-
dc.contributor.authorPoon, RTP-
dc.contributor.authorPastorelli, D-
dc.contributor.authorBlanc, JF-
dc.contributor.authorChung, HC-
dc.contributor.authorBaron, AD-
dc.contributor.authorOkusaka, T-
dc.contributor.authorBowman, L-
dc.contributor.authorCui, ZL-
dc.contributor.authorGirvan, AC-
dc.contributor.authorAbada, PB-
dc.contributor.authorYang, L-
dc.contributor.authorZhu, AX-
dc.date.accessioned2017-08-25T03:00:23Z-
dc.date.available2017-08-25T03:00:23Z-
dc.date.issued2017-
dc.identifier.citationEuropean Journal of Cancer, 2017, v. 81, p. 17-25-
dc.identifier.urihttp://hdl.handle.net/10722/243854-
dc.languageeng-
dc.relation.ispartofEuropean Journal of Cancer-
dc.subjectHepatocellular carcinoma-
dc.subjectPatient-focused outcomes-
dc.subjectPerformance status-
dc.subjectQuality of life-
dc.subjectRamucirumab-
dc.subjectSorafenib-
dc.titleRamucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study-
dc.typeArticle-
dc.identifier.emailPoon, RTP: poontp@hku.hk-
dc.identifier.authorityPoon, RTP=rp00446-
dc.identifier.doi10.1016/j.ejca.2017.05.001-
dc.identifier.scopuseid_2-s2.0-85019968389-
dc.identifier.hkuros274745-
dc.identifier.volume81-
dc.identifier.spage17-
dc.identifier.epage25-
dc.identifier.isiWOS:000404894700003-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats